SIGN IN
Medical Content and Scientific Strategy - Summer Intern jobs in United States
cer-icon
Apply on Employer Site
company-logo

Ascendis Pharma · 1 day ago

Medical Content and Scientific Strategy - Summer Intern

Ascendis Pharma is a dynamic, growing biopharma company advancing programs in Endocrinology Rare Disease, Oncology, and Ophthalmology. They are seeking a US Medical Content and Scientific Strategy Summer Intern to support the development and execution of scientific communication initiatives across the Medical Affairs organization.
BiotechnologyClinical TrialsHealth Care

Responsibilities

Assist in the development of scientific presentations, congress activities, training materials, and scientific field resources by working closely with US Medical Affairs Team and vendors
Assist with the management of timelines, milestones, and deliverables
Participate in team meetings and contribute to brainstorming sessions
Conduct research and analysis for ongoing projects
Provide administrative support as needed
Other duties as assigned

Qualification

PharmD programBiomedical sciencesMicrosoft OfficeQuick learnerCollaboration skillsOrganizational skillsCommunication skillsPresentation skillsTime managementDetail-oriented

Required

Currently enrolled in a PharmD program and completed P1 year or on a graduate-level track in the biomedical sciences (e.g. PhD)
Proficiency in all aspects of Microsoft office
Strong collaboration and organizational skills
Excellent communication, presentation, organizational and time management skills
Detail-oriented
Ability to quickly learn a new scientific discipline or concept

Benefits

Opportunity for mentorship and professional development

Company

Ascendis Pharma

twittertwittertwitter
company-logo
Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment paradigms.

Funding

Current Stage
Public Company
Total Funding
$1.88B
Key Investors
Royalty PharmaOrbiMed,Sofinnova Investments,Vivo CapitalGilde Healthcare,Sofinnova Partners
2024-09-19Post Ipo Equity· $300M
2024-09-03Post Ipo Debt· $150M
2023-09-05Post Ipo Debt· $150M

Leadership Team

leader-logo
Ivanna Rosendal
Senior Director, IT Business Partner
linkedin
leader-logo
Keren Tenenbaum
US General Counsel and Chief Compliance Officer
linkedin
Company data provided by crunchbase